ArticleScientific reports2025
Identification and validation of SAC3D1 as a prognostic biomarker promoting the development of osteosarcoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a highly malignant bone tumor that primarily affects children, adolescents, and young adults. Despite significant progress in chemotherapy, surgery, and limb salvage surgery, the prognosis for patients with high-grade or metastatic OS remains poor. This study explores the role of SAC3D1 gene in OS and its potential as a prognostic marker and therapeutic target. Through analysis of public databases and experimental verification, we found that SAC3D1 is significantly upregulated in OS tissues and cell lines and is associated with poor prognosis in patients. Functional enrichment analysis suggests that SAC3D1 may promote the progression of OS by regulating cell cycle, DNA repair, and immune microenvironment pathways. In addition, the expression level of SAC3D1 is associated with the tumor immune microenvironment and immune therapy response. In vitro experiments further confirmed that knocking down SAC3D1 significantly inhibited the proliferation, migration, and invasion ability of OS cells, while its overexpression enhanced these malignant biological behaviors. In summary, SAC3D1 has important prognostic and therapeutic potential in OS, and may serve as a novel independent prognostic marker and therapeutic target for OS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.